Clinical characteristics and prognostic implications in patients with HER2-low breast cancer undergoing neoadjuvant chemotherapy: a retrospective cohort study

被引：0
|
作者：
Zheng, Ang [1 ]
He, Junlin [2 ]
Li, Muyao [1 ]
Yao, Fan [1 ]
Jin, Feng [1 ]
Chen, Bo [1 ]
Wang, Xin [2 ]
机构：
[1] China Med Univ, Hosp 1, Shenyang, Peoples R China
[2] China Med Univ, Shenyang, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2025年 / 55卷
关键词：
HER2; Low; Breast Cancer;
D O I：
10.1016/j.lanwpc.2024.101378
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
    Ma, Youzhao
    Zhu, Mingda
    Zhang, Jingyang
    Lv, Minhao
    Chen, Xiuchun
    Liu, Zhenzhen
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1210 - 1221
  • [32] Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy
    Li, Xiaoping
    Lin, Zhiquan
    Yu, Qihe
    Qiu, Chaoran
    Lai, Chan
    Huang, Hui
    Zhang, Yiwen
    Zhang, Weibin
    Zhu, Jintao
    Huang, Xin
    Li, Weiwen
    GLAND SURGERY, 2023, : 183 - 196
  • [33] Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
    Lei-Jie Dai
    Ding Ma
    Yu-Zheng Xu
    Ming Li
    Yu-Wei Li
    Yi Xiao
    Xi Jin
    Song-Yang Wu
    Ya-Xin Zhao
    Han Wang
    Wen-Tao Yang
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Communications, 14
  • [34] HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    François Cherifi
    Angélique Da Silva
    Alison Johnson
    Cécile Blanc-Fournier
    Olivia Abramovici
    Antonin Broyelle
    Christelle Levy
    Djelila Allouache
    Ioana Hrab
    Carine Segura
    Adeline Morel
    Maud Villemin
    Clémence Boscher
    Coraline Dubot-Poitelon
    Pauline Rottier
    Justine Lequesne
    George Emile
    BMC Cancer, 22
  • [35] Analyzing Neoadjuvant Chemotherapy Effects in HER2-Low Breast Cancer: Real World Data
    Antonini, Marcelo
    Mattar, Andre
    Richter, Fernanda G.
    Ramos, Marcellus N.
    Teixeira, Marina D.
    Pantarotto, Nathalia N.
    Matta, Nadia F.
    Amorim, Andressa G.
    Pinheiro, Denise J.
    Lopes, Reginaldo C.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [36] Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
    Dai, Lei-Jie
    Ma, Ding
    Xu, Yu-Zheng
    Li, Ming
    Li, Yu-Wei
    Xiao, Yi
    Jin, Xi
    Wu, Song-Yang
    Zhao, Ya-Xin
    Wang, Han
    Yang, Wen-Tao
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [37] Analysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study
    Lasham, Annette
    Ramsaroop, Reenadevi
    Wrigley, Abbey
    Knowlton, Nicholas
    CANCERS, 2024, 16 (18)
  • [38] HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    Cherifi, Francois
    Da Silva, Angelique
    Johnson, Alison
    Blanc-Fournier, Cecile
    Abramovici, Olivia
    Broyelle, Antonin
    Levy, Christelle
    Allouache, Djelila
    Hrab, Ioana
    Segura, Carine
    Morel, Adeline
    Villemin, Maud
    Boscher, Clemence
    Dubot-Poitelon, Coraline
    Rottier, Pauline
    Lequesne, Justine
    Emile, George
    BMC CANCER, 2022, 22 (01)
  • [39] Retrospective analysis of HER2-low in young breast cancer patients.
    Omar, Abeid Mohamed Athman
    Darwish, Azza Mohamad Amin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications
    Tarantino, P.
    Niman, S. L.
    Erick, T.
    Priedigkeit, N.
    Harrison, B.
    Giordano, A.
    Nakhlis, F.
    Bellon, J. R.
    Parker, T.
    Strauss, S.
    Jin, Q.
    King, T. A.
    Overmoyer, B.
    Curigliano, G.
    Regan, M.
    Tolaney, S.
    Lynce, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S629 - S630
12345